Catalyst Pharmaceuticals (CPRX) Tax Provisions (2019 - 2026)

Catalyst Pharmaceuticals has reported Tax Provisions for 8 years, with the latest figure at $20.5 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 40.87% year-over-year to $20.5 million; the trailing twelve-month figure through Mar 2026 stood at $81.9 million (up 16.07% YoY), and the FY2025 full-year result was $76.0 million, up 22.85% from the prior year.
• Tax Provisions for Q1 2026 stood at $20.5 million, down from $26.0 million in the prior quarter.
• The five-year high for Tax Provisions was $29.7 million in Q4 2023, with the low at -$7.3 million in Q3 2023.
• Historically, Tax Provisions has averaged $12.5 million across 5 years, with a median of $13.3 million in 2024.
• The largest YoY upside for Tax Provisions was 2482.97% in 2023 against a maximum downside of 322.68% in 2023.
• Catalyst Pharmaceuticals' Tax Provisions stood at -$1.2 million in 2022, then soared by 2482.97% to $29.7 million in 2023, then declined by 6.64% to $27.7 million in 2024, then fell by 6.25% to $26.0 million in 2025, then fell by 21.08% to $20.5 million in 2026.
• The last three Tax Provisions figures came in at $20.5 million (Q1 2026), $26.0 million (Q4 2025), and $18.3 million (Q3 2025), per Business Quant data.